Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Dermatology Immune Disorders Infectious Diseases

Positive Phase IIb data from AstraZeneca in lupus and RA but PhIII not assured

This article was originally published in Scrip

Executive Summary

AstraZeneca's MedImmune unit has presented positive Phase IIb data at the American College of Rheumatology (ACR) meeting this week from two products highlighted by CEO Pascal Soriot as 'ones to watch' as he fended off Pfizer's unwanted advances earlier this year (scripintelligence.com, 28 May 2014). However, their progress into Phase III is not assured as AstraZeneca is waiting on data from other trials before making a decision on how to proceed.

Table

View full table

Topics

Related Companies

Tags:
Dermatology Immune Disorders Infectious Diseases
Latest Headlines

Diversification Gains Momentum As Companies Look To Derisk China

Finance Watch: Earnings Season Brings Job Cuts, Even At Big Pharma

JLABS Korea, The Next Evolution Of J&J’s Innovation Model

Newron’s Add-On Treatment Shows Promise In Newly Popular Schizophrenia Field

See All
UsernamePublicRestriction

Register

SC026955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By